Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 12,600 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The stock was bought at an average cost of $6.16 per share, with a total value of $77,616.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $18,904,738.16. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, July 12th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was bought at an average cost of $6.12 per share, with a total value of $22,032.00.
  • On Monday, July 10th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $6.19 per share, with a total value of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The stock was bought at an average cost of $6.29 per share, with a total value of $157,250.00.
  • On Monday, July 3rd, Phillip Md Et Al Frost acquired 60,800 shares of Opko Health stock. The stock was bought at an average cost of $6.44 per share, with a total value of $391,552.00.
  • On Friday, June 30th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was bought at an average cost of $6.58 per share, with a total value of $23,688.00.
  • On Wednesday, June 28th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was bought at an average cost of $6.87 per share, with a total value of $12,366.00.
  • On Tuesday, June 27th, Phillip Md Et Al Frost acquired 21,800 shares of Opko Health stock. The stock was bought at an average cost of $6.77 per share, with a total value of $147,586.00.
  • On Monday, June 26th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was bought at an average cost of $6.97 per share, with a total value of $12,546.00.
  • On Thursday, June 22nd, Phillip Md Et Al Frost acquired 131,000 shares of Opko Health stock. The stock was bought at an average cost of $6.72 per share, with a total value of $880,320.00.
  • On Thursday, June 15th, Phillip Md Et Al Frost acquired 200,000 shares of Opko Health stock. The stock was bought at an average cost of $6.43 per share, with a total value of $1,286,000.00.

Opko Health, Inc. (OPK) traded down 1.1436% during midday trading on Monday, hitting $6.0599. 625,824 shares of the stock traded hands. The stock’s 50-day moving average price is $6.59 and its 200 day moving average price is $8.10. Opko Health, Inc. has a 52 week low of $5.99 and a 52 week high of $12.15. The company’s market capitalization is $3.39 billion.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.02. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The firm had revenue of $296.10 million for the quarter, compared to the consensus estimate of $313.36 million. During the same quarter in the prior year, the company earned ($0.02) earnings per share. The company’s quarterly revenue was up 1.8% compared to the same quarter last year. On average, equities research analysts predict that Opko Health, Inc. will post ($0.20) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/opko-health-inc-nasdaqopk-ceo-phillip-md-et-al-frost-buys-12600-shares/1445193.html.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock worth $210,576,000 after buying an additional 1,112,843 shares in the last quarter. BlackRock Inc. raised its stake in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock worth $181,163,000 after buying an additional 22,449,752 shares in the last quarter. State Street Corp raised its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after buying an additional 3,138,685 shares in the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its stake in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock worth $40,489,000 after buying an additional 1,944,549 shares in the last quarter. Finally, Norges Bank purchased a new stake in Opko Health during the fourth quarter worth approximately $30,421,000. Institutional investors own 23.65% of the company’s stock.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $19.50 price target on shares of Opko Health in a research report on Friday, June 16th. BidaskClub upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Jefferies Group LLC restated a “hold” rating and issued a $8.00 price target on shares of Opko Health in a research report on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Opko Health presently has an average rating of “Hold” and an average price target of $16.58.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.